Aquestive Therapeutics (AQST) Stock 2026 Review

Mika L.
Written by Mika L.
Financial Content Writer

Aquestive Therapeutics3.5/5

AQST (NASDAQ)

Dividend yield
no dividend
1-Year Return
12.86%
5-Year Return
-33.40%

Aquestive Therapeutics (AQST) has been highlighted on the MarketBeat watchlist due to its notable trading activity, reflecting investor interest. With a 12-month price target set at $12, analysts maintain a consensus rating of Buy, indicating confidence in the stock's potential to rebound from its 5-year return of -33.40%. However, investors should be cautious, as the company faces regulatory challenges and financial pressures related to its lead product, Anaphylm.

Pros:

  • Strong recent trading activity
  • Diverse product pipeline

Cons:

  • Dependence on regulatory approval
  • Ongoing financial strain

In summary, Aquestive Therapeutics (AQST) may be suitable for risk-tolerant investors who are looking for potential growth opportunities, given its recent positive trading activity and analysts' consensus rating of Buy. However, prospective investors should carefully consider the company's ongoing regulatory challenges and financial pressures before making investment decisions.

Frequently Asked Questions